Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: miR-182 promoter hypermethylation predicts the better outcome of AML patients treated with AZA + VEN in a real-world setting

Fig. 5

Different methylation frequencies in AML patients at diagnosis, with CR/CRi, and in relapse. A Methylation frequency at the miR-182 promoter was measured in AML patients at diagnosis and in AML patients achieving CR/CRi. B Methylation frequency at the miR-182 promoter was measured in AML patients achieving CR/CRi and in relapsed AML patients. *P < 0.05

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us